IFF Earnings Call Highlights Growth, Portfolio Reset
International Flavors & Fragrances ((IFF)) has held its Q2 earnings call. Read on for the main highlights of the call.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
International Flavors & Fragrances’ latest earnings call struck a confident tone, underscoring solid operational momentum and strategic focus despite near‑term complications. Management highlighted volume‑driven growth across its core Taste, Scent and Health & Biosciences businesses, sharply better free cash flow and a transformative divestiture of Food Ingredients, while acknowledging cost, working‑capital and geopolitical headwinds that widen the range of outcomes.
Continuing Operations Deliver Top-Line and EBITDA Growth
IFF reported that its continuing operations posted 4% sales growth and an 8% increase in EBITDA in the first half of 2026, supported largely by volume gains and productivity improvements rather than price alone. Management framed this as evidence that the core portfolio is benefiting from demand recovery and internal efficiency programs, giving investors more confidence in the durability of the growth trend.
Second-Quarter Revenue and Profitability Strength
In the second quarter, revenue from continuing operations came in just under $2.0 billion, up about 6% year over year, while adjusted operating EBITDA rose 6% to $408 million. The company emphasized that this performance reflects broad‑based contribution from key segments and demonstrates its ability to grow earnings in line with sales, even as it navigates portfolio changes and a volatile macro backdrop.
Segment Performance Across Taste, Scent and Health & Biosciences
Taste sales increased 4% to $688 million, with EBITDA up 6% to $124 million and Asia delivering double‑digit growth that stood out as a regional bright spot. Health & Biosciences posted 5% sales growth to $601 million and 6% EBITDA growth to $150 million, while Scent grew sales 8% to $665 million and EBITDA 5% to $134 million, driven by more than 20% growth in Fragrance Ingredients in Q2.
Marked Improvement in Free Cash Flow and Cash Generation
Free cash flow in the first half surged to $378 million, an increase of $284 million versus the prior year, signaling better cash discipline and lower cash drains. Operating cash flow reached $679 million, while year‑to‑date capital expenditures were $301 million, roughly 5% of sales, as IFF continued to invest in its platform while tightening cash conversion.
Food Ingredients Divestiture Reshapes the Portfolio
The headline strategic move was the announced sale of the Food Ingredients business to CVC for around $4.3 billion, implying roughly 10x EV/EBITDA. Post‑transaction, IFF intends to focus squarely on higher‑growth, higher‑margin Taste, Scent and Health & Biosciences, while retaining a 10% stake in the sold business to participate in future upside without bearing operational complexity.
Further Portfolio Simplification Initiatives
IFF also reached an agreement to divest a set of nonstrategic assets, including botanical extracts, vitamins and minerals and certain food enhancement products that together generate about $170 million in annual sales. These assets carry only mid‑single‑digit EBITDA margins, and the expected proceeds of roughly $75 million, also at about a 10x multiple, underline the company’s push to streamline and upgrade portfolio quality.
Capital Allocation: Buybacks and Deleveraging
The board authorized a $2.5 billion share repurchase program, including roughly $400 million previously approved, with about $500 million planned for the second half of 2026 to return cash to shareholders. At the same time, management aims to use more than $1 billion of divestiture proceeds to reduce debt, having already improved net debt to credit‑adjusted EBITDA to about 2.5x at the end of H1 2026 from 4.5x at the start of 2024.
Stranded Costs Weighing on Near-Term Margins
The Food Ingredients sale will leave roughly $100 million of corporate and functional costs stranded at IFF once the deal closes, temporarily depressing business unit margins. Management laid out a remediation plan to remove about two‑thirds of these costs within 12 months and the remainder in the second full year after closing, suggesting a visible path to margin repair.
Working Capital and Cash Flow Headwinds from Separation
Management cautioned that second‑half cash flow will face net working capital headwinds linked to the Food Ingredients carve‑out, including unwinding factoring programs, shifts in receivables, inventory moves and supplier prepayments. The chief financial officer estimated this could amount to a “couple hundred million dollars” of cash impact, injecting timing uncertainty into the otherwise improving free cash flow picture.
Input Cost Inflation and Pricing Dynamics
IFF expects modest increases in input costs in the second half of the year, spanning raw materials, energy and logistics, with the Scent segment most exposed. The company acknowledged pricing lag in some areas, particularly Scent, and said it is actively working with customers to recover these higher costs, which could influence margin progression in the short term.
Geopolitical Volatility Hits Fine Fragrance
Management noted that conflict in the Middle East has introduced additional uncertainty for Fine Fragrance, compounding already tough comparisons against strong Q3 2025 results. As a result, IFF anticipates a softer third quarter in Fine Fragrance before a recovery in the fourth quarter, and widened its guidance ranges to reflect the broader geopolitical and demand volatility.
One-Time Items Distorting Q2 Profitability View
Second‑quarter reported results included two notable one‑offs: U.S. tariff refunds, which were booked as a benefit but offset by pass‑throughs to customers, and higher incentive compensation accruals tied to robust first‑half performance. These items muddied the picture of underlying leverage, with management suggesting that core profitability trends remain healthier than headline figures imply.
Reporting Changes Pressure Margins from Discontinued Ops
Classifying Food Ingredients as discontinued operations shifts associated stranded costs into the continuing businesses, creating temporary margin pressure and complicating period‑to‑period comparisons. Executives stressed that this accounting change does not reflect deterioration in the underlying economics of Taste, Scent and Health & Biosciences, but rather a transitional effect of the portfolio reshaping.
Timing Uncertainty in Free Cash Flow Conversion
While IFF expects full‑year free cash flow to exceed 2025 levels, the combination of transaction‑related working capital unwind and separation activities makes the rhythm of cash conversion in the second half harder to predict. Investors were told to focus less on quarterly lumpiness and more on the medium‑term trajectory, where cash generation is targeted to steadily improve.
Fragrance Ingredients Growth Faces Normalization Risk
The standout more than 20% growth in Fragrance Ingredients in Q2 was partly driven by an easy prior‑year comparison and tactical synthetic‑sourcing advantages, rather than purely structural demand. Management warned that some normalization is likely, meaning growth in this subsegment may moderate going forward, even though the broader Scent franchise remains on a solid footing.
Forward-Looking Guidance and Financial Outlook
IFF introduced 2026 guidance for continuing operations with sales expected between $7.4 billion and $7.6 billion, implying 2%–4% growth versus a pro forma 2025 base, and adjusted EBITDA of $1.53 billion–$1.60 billion, or 4%–8% growth. With FX forecast to provide a modest tailwind and free cash flow projected to rise despite working‑capital headwinds, the company aims to maintain CapEx at roughly 5%–6% of sales, keep R&D near 9% and SG&A at 17%–18%, while targeting longer‑term cash conversion in the mid‑ to high‑teens and net leverage of 2.0x–2.5x by end‑2027 alongside a staged $2.5 billion buyback.
Overall, International Flavors & Fragrances’ earnings call blended upbeat operational and strategic messages with a candid view of transitional challenges. The company is leaning into portfolio simplification, debt reduction and shareholder returns, while accepting near‑term cost, working‑capital and market volatility as the price of reshaping its profile, leaving investors with a cautiously optimistic medium‑term story.
